Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07033481 | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | PHASE2 | RECRUITING | 20 | — | — | Oct 2, 2025 | Oct 1, 2026 | Apr 22, 2026 | 7 | United States, United Kingdom |
The number and proportion of participants experiencing adverse events (AEs) and serious adverse events (SAEs) during the study period, categorized by severity and relationship to the study intervention.
| Arm | Type | Description |
|---|---|---|
| Neflamapimod | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Neflamapimod | DRUG | Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules |
| Placebo | DRUG | Placebo is a capsule that looks just like neflamapimod but without the active ingredients |
Inclusion Criteria: * Men and women aged 40-85 years at Screening. * Participant or participant's legally authorized representative (where applicable) is willing and able to provide written informed consent. * Clinical diagnosis of nfvPPA by consensus criteria \[Gorno-Tempini et al, 2011\]. * At...